|
10x Genomics, Inc. (TXG) DCF Valuation
US | Healthcare | Medical - Healthcare Information Services | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
10x Genomics, Inc. (TXG) Bundle
Evaluate 10x Genomics, Inc.'s financial outlook like an expert! This (TXG) DCF Calculator provides pre-filled financial data and offers full flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 298.8 | 490.5 | 516.4 | 618.7 | 610.8 | 745.1 | 908.9 | 1,108.7 | 1,352.5 | 1,649.8 |
| Revenue Growth, % | 0 | 64.13 | 5.28 | 19.81 | -1.28 | 21.99 | 21.99 | 21.99 | 21.99 | 21.99 |
| EBITDA | -513.8 | -24.6 | -128.5 | -205.1 | -134.0 | -275.7 | -336.3 | -410.2 | -500.4 | -610.4 |
| EBITDA, % | -171.92 | -5.01 | -24.88 | -33.15 | -21.94 | -37 | -37 | -37 | -37 | -37 |
| Depreciation | 19.0 | 28.3 | 33.0 | 43.6 | 43.7 | 48.8 | 59.5 | 72.6 | 88.5 | 108.0 |
| Depreciation, % | 6.36 | 5.76 | 6.39 | 7.05 | 7.16 | 6.54 | 6.54 | 6.54 | 6.54 | 6.54 |
| EBIT | -532.8 | -52.8 | -161.5 | -248.7 | -177.7 | -314.9 | -384.2 | -468.6 | -571.7 | -697.3 |
| EBIT, % | -178.28 | -10.77 | -31.27 | -40.2 | -29.09 | -42.27 | -42.27 | -42.27 | -42.27 | -42.27 |
| Total Cash | 663.6 | 587.4 | 430.0 | 388.7 | 393.4 | 611.7 | 746.2 | 910.2 | 1,110.4 | 1,354.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 51.2 | 85.3 | 104.2 | 114.8 | 87.9 | 130.6 | 159.3 | 194.3 | 237.1 | 289.2 |
| Account Receivables, % | 17.14 | 17.38 | 20.18 | 18.56 | 14.39 | 17.53 | 17.53 | 17.53 | 17.53 | 17.53 |
| Inventories | 30.0 | 60.0 | 81.6 | 73.7 | 83.1 | 94.7 | 115.6 | 141.0 | 172.0 | 209.8 |
| Inventories, % | 10.02 | 12.23 | 15.81 | 11.91 | 13.61 | 12.72 | 12.72 | 12.72 | 12.72 | 12.72 |
| Accounts Payable | 4.7 | 17.4 | 21.6 | 15.7 | 12.9 | 20.8 | 25.4 | 30.9 | 37.7 | 46.0 |
| Accounts Payable, % | 1.58 | 3.54 | 4.18 | 2.54 | 2.11 | 2.79 | 2.79 | 2.79 | 2.79 | 2.79 |
| Capital Expenditure | -38.4 | -101.3 | -131.7 | -49.5 | -12.4 | -102.9 | -125.5 | -153.1 | -186.7 | -227.8 |
| Capital Expenditure, % | -12.85 | -20.65 | -25.5 | -8 | -2.03 | -13.8 | -13.8 | -13.8 | -13.8 | -13.8 |
| Tax Rate, % | -2.77 | -2.77 | -2.77 | -2.77 | -2.77 | -2.77 | -2.77 | -2.77 | -2.77 | -2.77 |
| EBITAT | -541.0 | -57.3 | -165.5 | -255.1 | -182.6 | -314.9 | -384.2 | -468.6 | -571.7 | -697.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -636.9 | -181.7 | -300.5 | -269.5 | -136.6 | -415.5 | -495.1 | -604.0 | -736.8 | -898.8 |
| WACC, % | 12.22 | 12.22 | 12.22 | 12.22 | 12.22 | 12.22 | 12.22 | 12.22 | 12.22 | 12.22 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2,160.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -917 | |||||||||
| Terminal Value | -8,968 | |||||||||
| Present Terminal Value | -5,038 | |||||||||
| Enterprise Value | -7,199 | |||||||||
| Net Debt | -261 | |||||||||
| Equity Value | -6,937 | |||||||||
| Diluted Shares Outstanding, MM | 120 | |||||||||
| Equity Value Per Share | -57.59 |
What You Will Get
- Real 10x Genomics Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for 10x Genomics, Inc. (TXG).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis needs.
- Instant Valuation Updates: Automatic recalculations to assess the impact of changes on 10x Genomics’ fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections specific to 10x Genomics, Inc. (TXG).
- Time-Saving and Accurate: Avoid building models from scratch while ensuring precision and flexibility in your evaluations.
Key Features
- Comprehensive Data: 10x Genomics’ historical financial statements and pre-filled projections.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: View 10x Genomics’ intrinsic value update instantly.
- Visual Data Representation: Interactive dashboard charts showcase valuation results and essential metrics.
- Designed for Precision: A specialized tool for analysts, investors, and finance professionals.
How It Works
- Download: Get the pre-configured Excel file containing 10x Genomics, Inc.'s (TXG) financial information.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and instantly compare results.
- Make Decisions: Utilize the valuation findings to inform your investment approach.
Why Choose This Calculator for 10x Genomics, Inc. (TXG)?
- Accurate Data: Real 10x Genomics financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to match your projections.
- Time-Saving: Pre-built calculations eliminate the need to start from scratch.
- Professional-Grade Tool: Designed for investors, analysts, and consultants in the genomics field.
- User-Friendly: Intuitive layout and step-by-step instructions make it easy for all users.
Who Should Use This Product?
- Investors: Evaluate 10x Genomics’ valuation before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation processes and assess future projections.
- Biotech Entrepreneurs: Understand how leading biotech firms like 10x Genomics are valued.
- Consultants: Provide comprehensive valuation reports to clients in the biotech sector.
- Students and Educators: Utilize real-world data to learn and teach valuation methodologies.
What the Template Contains
- Pre-Filled Data: Includes 10x Genomics, Inc.'s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze 10x Genomics, Inc.'s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.